Retatrutide, a fairly emerging compound, has sparked considerable interest within the research area due to its potential impact on obesity treatment. Ongoing studies indicate that this integrated activator of incretin and GIP receptors exhibits positive results in human testing, arguably driving to greater weight reduction compared to available med